Autologous stem cell transplant for early relapsed/refractory Hodgkin lymphoma: results from two transplant centres
- 16 March 2011
- journal article
- research article
- Published by Wiley in British Journal of Haematology
- Vol. 153 (3) , 358-363
Abstract
Summary: Prior series have demonstrated that early relapsed (within 1 year) or refractory Hodgkin lymphoma (HL) is associated with poor prognosis. To determine the outcome for patients with early relapsed/refractory HL in the modern era, we combined data from two large transplant centres, Cleveland Clinic Taussig Cancer Institute (CCTCI) and Memorial Sloan‐Kettering Cancer Center (MSKCC), and analysed consecutive patients transplanted for relapsed/refractory HL following induction failure or remission durations of <1 year. Two hundred and fourteen patients were analysed and the event‐free survival (EFS) and overall survival (OS) at 6 years for all patients were 45% and 55%, respectively. Factors significant for prognosis in multivariate analysis were extranodal disease and bulky disease (≥5 cm). Patients with 0, 1, or 2 risk factors achieved 6 year EFS of 65%, 47%, and 24% and 6 year OS of 81%, 55%, and 27%, respectively. Patients with the sole risk factor of early relapsed/refractory disease achieved good outcomes in this large series; however the presence of bulk and/or extranodal disease significantly reduced EFS and OS. Patients with these additional risk factors are best suited for clinical trials investigating novel salvage regimens and post‐transplant maintenance strategies.Keywords
This publication has 21 references indexed in Scilit:
- Dose Intensity of Chemotherapy in Patients With Relapsed Hodgkin's LymphomaJournal of Clinical Oncology, 2010
- Long-Term Follow-up of Survival in Hodgkin's LymphomaNew England Journal of Medicine, 2009
- Ongoing improvement in long-term survival of patients with Hodgkin disease at all ages and recent catch-up of older patientsBlood, 2008
- Tandem Autologous Stem Cell Transplantation for Patients with Primary Refractory or Poor Risk Recurrent Hodgkin LymphomaTransplantation and Cellular Therapy, 2007
- Randomized Comparison of ABVD and MOPP/ABV Hybrid for the Treatment of Advanced Hodgkin’s Disease: Report of an Intergroup TrialJournal of Clinical Oncology, 2003
- Intensive Salvage Therapy With High-Dose Chemotherapy for Patients With Advanced Hodgkin's Disease in Relapse or Failure After Initial Chemotherapy: Results of the Groupe d'Etudes des Lymphomes de l'Adulte H89 TrialJournal of Clinical Oncology, 2002
- A Prognostic Score for Advanced Hodgkin's DiseaseNew England Journal of Medicine, 1998
- Prognostic factors for survival after high-dose therapy and autologous stem cell transplantation for patients with relapsing Hodgkin’s disease: analysis of 280 patients from the French registryBone Marrow Transplantation, 1997
- Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trialThe Lancet, 1993
- Chemotherapy of Advanced Hodgkin's Disease with MOPP, ABVD, or MOPP Alternating with ABVDNew England Journal of Medicine, 1992